EffectorMed
EffectorMed is an ambitious project pioneering groundbreaking Targeted Protein Degradation (TPD) technology.
TPD technologies have gained significant attention in drug discovery due to their ability to target and degrade disease-causing proteins.
We aim to develop new treatments of pathologies involving altered or unwanted proteins accumulation. It concerns chronic diseases (AATLD), neurodegenerative diseases (Alzeimer, Parkinson, ALS) and cancers.
The Technology
The project builds on the innovative work of TSL adjunct-scientist Professor Saskia Hogenhout and her team at the John Innes Centre.
A protein-based targeted protein degradation technology able to short-circuit the Ubiquitin Proteasome System (UPS).
Our new degrader(s) are able to directly interact with the proteasome to degrade the target protein, bypassing the need for E3 ligases which can be altered in some diseases.
Unlike PROTACs, our degraders do not rely on E3 ligases for TPD activity, allowing for broader applicability and reduced specificity constraints.
Thanks to to their protein-based nature, our degrader(s) can be rapidly bioengineered for high target specificity, minimising potential side effects. Also, their catalytic activity enables effective results with minimal quantities.
Their ability to be bioengineered allow us to have a vast range of targets, addressing multiple diseases and markets, but most importantly, it allows us to transform the lives of millions of patients.
Timeline & Next Steps
Unlock Full Potential: Validate the complete humanization of our degraders and prove their efficacy in human cells, paving the way for transformative therapies.
Engineer for Impact: Bioengineer our degraders to target and neutralize key disease-causing proteins, revolutionizing precision medicine.
Partner for Progress: Join forces with us to tackle preclinical challenges and accelerate the journey from lab to lifesaving treatments.